Transient removal of CD46 is safe and increases B-cell depletion by rituximab in CD46 transgenic mice and macaques

Molecular Therapy

Volumn 21, Issue 2, 2013, Pages 291-299

  Beyer, Ines ^a,f   Cao, Hua ^a   Persson, Jonas ^a   Wang, Hongjie ^a   Liu, Ying ^a   Yumul, Roma ^a   Li, Zongyi ^a   Woodle, Douglas ^c   Manger, Ronald ^c   Gough, Michael ^d   Rocha, Diane ^d   Bogue, Jaclyn ^d   Baldessari, Audrey ^d   Berenson, Ronald ^e   Carter, Darrick ^e   Lieber, André ^a,b,e  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d Washington National Primate Research Center   (United States)

^e Compliment Corp ^*  (United States)

^f HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CD20 ANTIBODY; COMPLEMENT REGULATORY PROTEIN; MEMBRANE COFACTOR PROTEIN; RECOMBINANT PROTEIN; REGULATOR PROTEIN; RITUXIMAB; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CANCER COMBINATION CHEMOTHERAPY; CELL SURFACE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; LYMPHOCYTE DEPLETION; MACACA; MALE; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; PROTEIN DEGRADATION; PROTEIN DEPLETION; TRANSGENIC MOUSE; TUMOR CELL; TUMOR XENOGRAFT;

ANIMALIA; ESCHERICHIA COLI; MACACA; MURINAE; MUS MUSCULUS; PRIMATES;

EID: 84873407750     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.212     Document Type: Article

References (41)

1. Boye, J, Elter, T and Engert, A (2003). An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 14: 520-535.
2. Molina, A (2008). A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma. Annu Rev Med 59: 237-250.
3. Pulte, D, Gondos, A and Brenner, H (2012). Expected long-term survival of older patients diagnosed with non-Hodgkin lymphoma in 2008-2012. Cancer Epidemiol 36: e19-e25.
4. Di Gaetano, N, Cittera, E, Nota, R, Vecchi, A, Grieco, V, Scanziani, E et al. (2003). Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 171: 1581-1587.
5. Golay, J, Cittera, E, Di Gaetano, N, Manganini, M, Mosca, M, Nebuloni, M et al. (2006). The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. Haematologica 91: 176-183.
6. Reff, ME, Carner, K, Chambers, KS, Chinn, PC, Leonard, JE, Raab, R et al. (1994). Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83: 435-445.
7. Bellosillo, B, Villamor, N, López-Guillermo, A, Marcé, S, Esteve, J, Campo, E et al. (2001). Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Blood 98: 2771-2777.
8. van der Kolk, LE, Grillo-López, AJ, Baars, JW, Hack, CE and van Oers, MH (2001). Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol 115: 807-811.
9. Marie, JC, Astier, AL, Rivailler, P, Rabourdin-Combe, C, Wild, TF and Horvat, B (2002). Linking innate and acquired immunity: divergent role of CD46 cytoplasmic domains in T cell induced infammation. Nat Immunol 3: 659-666.
10. Weiner, GJ (2010). Rituximab: mechanism of action. Semin Hematol 47: 115-123.
11. Hara, T, Kojima, A, Fukuda, H, Masaoka, T, Fukumori, Y, Matsumoto, M et al. (1992). Levels of complement regulatory proteins, CD35 (CR1), CD46 (MCP) and CD55 (DAF) in human haematological malignancies. Br J Haematol 82: 368-373.
12. Zell, S, Geis, N, Rutz, R, Schultz, S, Giese, T and Kirschfnk, M (2007). Down-regulation of CD55 and CD46 expression by anti-sense phosphorothioate oligonucleotides (S-ODNs) sensitizes tumour cells to complement attack. Clin Exp Immunol 150: 576-584.
13. Wang, H, Liu, Y, Li, ZY, Fan, X, Hemminki, A and Lieber, A (2010). A recombinant adenovirus type 35 fber knob protein sensitizes lymphoma cells to rituximab therapy. Blood 115: 592-600.
14. Ong, HT, Timm, MM, Greipp, PR, Witzig, TE, Dispenzieri, A, Russell, SJ et al. (2006). Oncolytic measles virus targets high CD46 expression on multiple myeloma cells. Exp Hematol 34: 713-720.
15. Gaggar, A, Shayakhmetov, DM and Lieber, A (2003). CD46 is a cellular receptor for group B adenoviruses. Nat Med 9: 1408-1412.
16. Wang, H, Liu, Y, Li, Z, Tuve, S, Stone, D, Kalyushniy, O et al. (2008). In vitro and in vivo properties of adenovirus vectors with increased affnity to CD46. J Virol 82: 10567-10579.
17. Ni, S, Gaggar, A, Di Paolo, N, Li, ZY, Liu, Y, Strauss, R et al. (2006). Evaluation of adenovirus vectors containing serotype 35 fbers for tumor targeting. Cancer Gene Ther 13: 1072-1081.
18. Ahuja, A, Shupe, J, Dunn, R, Kashgarian, M, Kehry, MR and Shlomchik, MJ (2007). Depletion of B cells in murine lupus: effcacy and resistance. J Immunol 179: 3351-3361.
19. Daydé, D, Ternant, D, Ohresser, M, Lerondel, S, Pesnel, S, Watier, H et al. (2009). Tumor burden infuences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20. Blood 113: 3765-3772.
20. Adams, S, Miller, GT, Jesson, MI, Watanabe, T, Jones, B and Wallner, BP (2004). PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism. Cancer Res 64: 5471-5480.
21. Adams, WC, Berenson, RJ, Karlsson Hedestam, GB, Lieber, A, Koup, RA and Loré, K (2012). Attenuation of CD4+ T-cell function by human adenovirus type 35 is mediated by the knob protein. J Gen Virol 93(Pt 6): 1339-1344.
22. Adams, WC, Gujer, C, McInerney, G, Gall, JG, Petrovas, C, Karlsson Hedestam, GB et al. (2011). Adenovirus type-35 vectors block human CD4+ T-cell activation via CD46 ligation. Proc Natl Acad Sci USA 108: 7499-7504.
23. Hsu, EC, Dörig, RE, Sarangi, F, Marcil, A, Iorio, C and Richardson, CD (1997). Artifcial mutations and natural variations in the CD46 molecules from human and monkey cells defne regions important for measles virus binding. J Virol 71: 6144-6154.
24. Gaufn, T, Pattison, M, Gautam, R, Stoulig, C, Dufour, J, MacFarland, J et al. (2009). Effect of B-cell depletion on viral replication and clinical outcome of simian immunodefciency virus infection in a natural host. J Virol 83: 10347-10357.
25. Russell, SJ and Peng, KW (2009). Measles virus for cancer therapy. Curr Top Microbiol Immunol 330: 213-241.
26. Lanini, S, Molloy, AC, Fine, PE, Prentice, AG, Ippolito, G and Kibbler, CC (2011). Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis. BMC Med 9: 36.
27. van der Kolk, LE, Baars, JW, Prins, MH and van Oers, MH (2002). Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 100: 2257-2259.
28. Jordan, SC, Kahwaji, J, Toyoda, M and Vo, A (2011). B-cell immunotherapeutics: emerging roles in solid organ transplantation. Curr Opin Organ Transplant 16: 416-424.
29. From the Centers for Disease Control and Prevention. (1998). Civilian outbreak of adenovirus acute respiratory disease-South Dakota, 1997. JAMA 280: 596.
30. Roy, S, Gao, G, Lu, Y, Zhou, X, Lock, M, Calcedo, R et al. (2004). Characterization of a family of chimpanzee adenoviruses and development of molecular clones for gene transfer vectors. Hum Gene Ther 15: 519-530.
31. Kavanagh, D, Richards, A and Atkinson, J (2008). Complement regulatory genes and hemolytic uremic syndromes. Annu Rev Med 59: 293-309.
32. Winiarska, M, Glodkowska-Mrowka, E, Bil, J and Golab, J (2011). Molecular mechanisms of the antitumor effects of anti-CD20 antibodies. Front Biosci 16: 277-306.
33. Wang, SY and Weiner, G (2008). Complement and cellular cytotoxicity in antibody therapy of cancer. Expert Opin Biol Ther 8: 759-768.
34. Coiffer, B (2007). Rituximab therapy in malignant lymphoma. Oncogene 26: 3603-3613.
35. Ge, X, Wu, L, Hu, W, Fernandes, S, Wang, C, Li, X et al. (2011). rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia. Clin Cancer Res 17: 6702-6711.
36. You, T, Hu, W, Ge, X, Shen, J and Qin, X (2011). Application of a novel inhibitor of human CD59 for the enhancement of complement-dependent cytolysis on cancer cells. Cell Mol Immunol 8: 157-163.
37. Hu, W, Ge, X, You, T, Xu, T, Zhang, J, Wu, G et al. (2011). Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis. Cancer Res 71: 2298-2307.
38. DiPaolo, N, Ni, S, Gaggar, A, Strauss, R, Tuve, S, Li, ZY et al. (2006). Evaluation of adenovirus vectors containing serotype 35 fbers for vaccination. Mol Ther 13: 756-765.
39. Tuve, S, Chen, BM, Liu, Y, Cheng, TL, Touré, P, Sow, PS et al. (2007). Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses. Cancer Res 67: 5929-5939.
40. Lapalombella, R, Zhao, X, Triantafllou, G, Yu, B, Jin, Y, Lozanski, G et al. (2008). A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents. Clin Cancer Res 14: 569-578.
41. Lee, C, Dhillon, J, Wang, MY, Gao, Y, Hu, K, Park, E et al. (2008). Targeting YB-1 in HER-2 overexpressing breast cancer cells induces apoptosis via the mTOR/STAT3 pathway and suppresses tumor growth in mice. Cancer Res 68: 8661-8666.